지엘팜텍

204840KOSDAQ

42.5 / 100

Reference Date: 2026-10-23

Financial Score13.0 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Plunged 17.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

GELPAMTEK primarily operates in pharmaceutical R&D services and has expanded into drug distribution and marketing. Its subsidiary, GELPHARMA, focuses on pharmaceutical manufacturing and sales, with key products including gastritis treatments, neuropathic pain medications, and specialty drugs. The company also generates revenue through technology fees and royalties from licensing its improved new drug technologies.

Number of Employees

32people

Average Salary

46.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

4644.55Industry Average 15.000.0Point

309.6x industry avg (risky)

PBR

2.91Industry Average 1.200.0Point

2.4x industry avg (risky)

ROE

0.06Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

37.41Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲17.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲80.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -13.7% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (59%)

Current 3,740Won52-week high 5,73052-week low 780

1-month return0.0Point

1m -17.53% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0